Altimmune, Inc. announced on October 23, 2026, that it has appointed Peter Greenleaf and Alex Howarth to its Board of Directors. The appointments are effective November 2, 2026, and will increase the size of the board from nine to eleven members.
Peter Greenleaf, 54, most recently served as the Chief Executive Officer of Aurinia Pharmaceuticals Inc. (Nasdaq: AUPH). Prior to that, he was the CEO and Chairman of Sucampo Pharmaceuticals, Inc., overseeing its sale for approximately $1.2 billion. He also previously served as CEO of Cerecor Pharmaceuticals and Histogenics Corporation. Greenleaf currently serves as Chairman of Pelthos Therapeutics (Nasdaq: PTHS).
Alex Howarth, 58, most recently served as the Chief Financial Officer of Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) from May 2021 through May 2024. Prior to Madrigal, he was the Chief Operating Officer of Akcea Therapeutics, Inc. (Nasdaq: AKCA), leading its sale in a transaction valued at $2 billion. Howarth also previously served as President and CFO at Lycera Corporation.
As part of a planned transition, John M. Gill, Mitchel Sayare, Ph.D., and Klaus O. Schafer, M.D., MPH, will retire from the Board and not stand for re-election at the Company’s 2027 Annual Meeting. The resignations are not due to any disagreements with the Company on matters relating to its operations, policies, or practices.
The Company stated that the new directors will be compensated pursuant to its Non-Employee Director Compensation Policy. Each new director will receive an initial equity award of stock options to purchase 160,000 shares of the Company’s common stock and an annual cash retainer of $40,000.
